{
    "id": "5e30f494fbd6abf43b000044",
    "question": "Is Selinexor effective for multiple myeloma?",
    "options": {
        "A": "yes",
        "B": "no"
    },
    "answer": "A",
    "predict": "{\"step_by_step_thinking\": \"To determine the effectiveness of Selinexor for multiple myeloma, we need to consider the available clinical trial data and research findings. Selinexor is a selective inhibitor of the nuclear export protein XPO1, which is overexpressed in multiple myeloma cells and contributes to their survival and proliferation. Several clinical trials have investigated the efficacy of Selinexor in multiple myeloma patients, including those with relapsed or refractory disease. The results of these trials have shown that Selinexor can induce significant responses, including complete and partial responses, in a subset of patients. In addition, Selinexor has been shown to have a favorable safety profile, with manageable side effects compared to other treatments in the same class. The most common adverse events reported were fatigue, anemia, and diarrhea. Based on these findings, Selinexor appears to be an effective treatment option for multiple myeloma, particularly for patients who have failed or are intolerant to other therapies. However, it is essential to note that individual patient responses may vary, and the optimal use of Selinexor should be determined on a case-by-case basis. Given the available evidence, I conclude that Selinexor is effective for multiple myeloma.\", \"answer_choice\": \"A\"}",
    "snippets": [],
    "scores": [],
    "execution_time": 7.596765041351318
}